It was a delight to catch up with our Expert Faculty Member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), to discuss the recent phase 2 and 3 analyses of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib.
His abstract entitled ‘Herpes Zoster Infection in Patients with Ulcerative Colitis Receiving tofacitinib results from the Phase 2 and Phase 3 Clinical Programs’ (Fr5340) was presented at DDW, 21-23 May 2021.
- What has the tofacitinib UC clinical trial program taught us about the herpes zoster incidence during the induction and maintenance treatment of ulcerative colitis with tofacitinb? (0:17)
- Could you tell us a little about the analysis you presented at the Digestive Disease Week® (DDW) meeting, and its findings? (1:19)
- Which patients have the highest risk of herpes zoster? (3:19)
- What are the limitations of this analysis and what future studies are planned? (4:35)
Disclosures: Gil Y Melmed has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-Meyers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, Techlab, and has received research funding from Pfizer for an unrelated investigator-initiated study.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Detlef Schuppan, UEG 2021: Transglutaminase 2 Inhibitor in Celiac Disease
touchIMMUNOLOGY caught up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) to talk about the results for the phase 2 study investigating the oral transglutaminase 2 inhibitor, ZED1227, in patients with celiac disease. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at […]
Detlef Schuppan, UEG 2021: Advances in the Management of Celiac Disease
It was a pleasure to catch up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) following his presentations at virtual UEG week to discuss the current unmet needs in the treatment of celiac disease and advances being made in its management. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN […]
Marc Ferrante, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!